Adult Dosing
Hodgkin lymphoma, Systemic anaplastic large cell lymphoma
- 1.8 mg/kg IV infusion over 30 minutes q3 wks for up to 16 cycles
Note:
- Use 100 kg dose for patients weighing more than 100 kg
- Do not administer as an intravenous push or bolus
- Continue treatment until a maximum of 16 cycles, disease progression or unacceptable toxicity
- Do not freeze
- Do not mix brentuximab vedotin with or administer as an infusion with, other medicinal products
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
[Outline]
- Therapy may cause peripheral neuropathy; monitor for sign of neuropathy such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain or weakness. patient who experience new or worsening peripheral neuropathy may require a delay, change in dose, or discontinuation of therapy
- Therapy may cause infusion related reaction such anaphylaxis, if such events occurs immediately and permanently discontinue the therapy and administer appropriate therapy; during infusion monitor the patient
- Premdicate the patient by giving acetaminophen, antihistamine and corticosteroid in patient who had experienced a prior infusion related reaction
- Monitor CBC prior to each dose and more frequently in patient with grade 3 or 4 neutropenia. Manage the patient by dose delays, reductions, or discontinuations if grade 3 or 4 neutropenia develops
- Therapy may cause tumor lysis syndrome and risk increases in patient with rapidly proliferating tumor and high tumor burden. Closely monitor and take appropriate measures
- Therapy may cause Stevens-Johnson Syndrome. if it occurs discontinue the therapy and administer appropriate medical therapy
- Cases of life threatening progressive multifocal leukoencephalopathy has been reported in patient who received 4 chemotherapy regimens prior to therapy
- Therapy may cause fetal harm in pregnant women. Pregnant woman or if patient becomes pregnant should be appraised of potential hazard to the fetus
- Progressive multifocal leukoencephalopathy (PML) has been reported
Cautions: Use cautiously in
- Peripheral neuropathy
- Neutropenia
- Rapidly proliferating tumor
- High tumor burden
Pregnancy Category:D
Breastfeeding: Safety unknown. According to manufacturer, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
